A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.Citation: Journal of Diabetes & its Complications. 31(12):1719-1727, 2017 Dec.PMID: 28939018Institution: MedStar Health Research InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Cardiovascular Diseases/pc [Prevention & Control] | *Diabetes Mellitus, Type 1/dt [Drug Therapy] | *Diabetes Mellitus, Type 2/dt [Drug Therapy] | *Diabetic Angiopathies/pc [Prevention & Control] | *Diabetic Cardiomyopathies/pc [Prevention & Control] | *Drug Labeling | *Hypoglycemic Agents/tu [Therapeutic Use] | Adult | Animals | Cardiovascular Diseases/ci [Chemically Induced] | Cardiovascular Diseases/co [Complications] | Cardiovascular Diseases/ep [Epidemiology] | Child | Diabetes Mellitus, Type 1/bl [Blood] | Diabetes Mellitus, Type 1/co [Complications] | Diabetes Mellitus, Type 2/bl [Blood] | Diabetes Mellitus, Type 2/co [Complications] | Diabetic Angiopathies/ci [Chemically Induced] | Diabetic Angiopathies/ep [Epidemiology] | Diabetic Angiopathies/mo [Mortality] | Diabetic Cardiomyopathies/ci [Chemically Induced] | Diabetic Cardiomyopathies/ep [Epidemiology] | Diabetic Cardiomyopathies/mo [Mortality] | Drug Approval | Drug Labeling/td [Trends] | Humans | Hyperglycemia/pc [Prevention & Control] | Hypoglycemia/ci [Chemically Induced] | Hypoglycemia/pc [Prevention & Control] | Hypoglycemic Agents/ae [Adverse Effects] | Hypoglycemic Agents/cl [Classification] | Risk | United States Food and Drug Administration | United States/ep [Epidemiology]Year: 2017ISSN:
|Item type||Current library||Collection||Call number||Status||Date due||Barcode|
|Journal Article||MedStar Authors Catalog||Article||28939018||Available||28939018|
AIMS: FDA-approved drug labels are an important source of information for clinicians who prescribe medications for treatment of diabetes. We reviewed drug labels to (1) understand the landscape of classes of medications approved for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), (2) explore the indications and safety information and (3) examine their cardiovascular safety.
CONCLUSIONS: All currently available diabetes medications are approved for adults with T2DM with a remarkably limited number for adults with T1DM and children with T1DM or T2DM. The incorporation of emerging data on cardiovascular outcomes in FDA drug labels is expected to influence the way physicians treat patients with diabetes. Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
METHODS: We searched four public references and reviewed all FDA-approved labels for "indication and usage," "adverse effects," "warnings and precautions," and "cardiovascular outcomes" from October 1982 to July 2016. We also reviewed FDA drug-safety communications from January 2015 to May 2017.
RESULTS: The labels reveal 12 classes of medications approved for T2DM with only 2 classes approved for T1DM. There is emerging evidence about cardiovascular safety and risk reduction from diabetes medications which is now being incorporated in drug labels.